Printer Friendly

ENDOTRONICS, INC. SIGNS STRATEGIC COOPERATION AGREEMENT WITH TECNOMARA AG OF SWITZERLAND

 MINNEAPOLIS, Jan. 7 /PRNewswire/ -- Endotronics, Inc. (NASDAQ: ENDO) today announced it has signed a strategic cooperation agreement with Tecnomara AG of Switzerland, whereby Tecnomara will have exclusive worldwide rights to manufacture and market the ACUMOUSE(TM) cell culture system for use in the area of research. As part of the agreement, Endotronics has received an initial fee of $1.5 million and ongoing royalties from future sales of the ACUMOUSE product. The ACUMOUSE is used for a variety of applications including research into treatments for cancer, AIDS, hepatitis and other diseases.
 Commenting on the licensing agreement, Richard E. Sakowicz, president and chief operating officer of Endotronics, said, "This marketing arrangement has important implications for Endotronics. The agreement leverages Tecnomara's sales and distribution resources and allows Endotronics' ACUMOUSE cell culture


system to be introduced into the research market worldwide on an accelerated schedule. The initial and ongoing revenues from the agreement are substantial, and will contribute to accelerating the revenue growth of the company's expanded cell culture product portfolio, thus strengthening Endotronics' leadership position in the bioprocessing marketplace."
 Endotronics jointly developed the ACUMOUSE with Tecnomara, which is the first instrument to house Endotronics' proprietary OXYCELL(TM) bioreactor technology. Tecnomara AG is a wholly owned subsidiary of INTEGRA Holding AG of Switzerland, a significant shareholder of Endotronics. Tecnomara AG has a broad line of research products and more than 25 years' experience as a supplier of products to the bioscientific markets of Europe. Areas of focus include cell biology, biotechnology and laboratory instrumentation, as well as strategic partnering in the life sciences area.
 Endotronics, Inc., headquartered in Minneapolis, is dedicated to providing cell processing products and services to meet the needs of human health care and biotechnology markets worldwide. The company is a recognized industry leader in mammalian cell culture instrumentation with more than 880 instruments installed worldwide.
 -0- 1/7/93
 /CONTACT: Yvonne L. Marschner-Bova, director, Investor Relations, Endotronics, Inc., 313-871-7350/
 (ENDO)


CO: Endotronics, Inc. ST: Minnesota IN: MTC SU: LIC

SB-JG -- DE009 -- 2572 01/07/93 10:22 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 7, 1993
Words:339
Previous Article:DOT APPROVES AIR CANADA/AIR PARTNERS INVESTMENT IN CONTINENTAL AIRLINES
Next Article:COCA-COLA NESTLE REFRESHMENTS COMPANY LAUNCHES NESTEA(R) POST-MIX FOUNTAIN ICED TEA
Topics:


Related Articles
ENDOTRONICS, INC. SIGNS AGREEMENT WITH GOODWIN INSTITUTE FOR CANCER RESEARCH INC. TO EXPAND CONTRACT PRODUCTION SERVICES
ENDOTRONICS DISCONTINUES DISTRIBUTION AGREEMENT WITH VENTREX LABORATORIES -- SIGNS LETTER OF INTENT WITH NORTHUMBRIA BIOLOGICALS
ENDOTRONICS, INC. RECEIVES $1 MILLION PURSUANT TO INVESTMENT AGREEMENT WITH INTEGRA HOLDING AG OF SWITZERLAND
ENDOTRONICS HOLDS ANNUAL MEETING OF SHAREHOLDERS: UPDATES INVESTMENT COMMUNITY ON ACUMOUSE AND ARTIFICIAL LIVER PROGRAM
ENDOTRONICS SIGNS PRODUCTION AND MARKETING AGREEMENT WITH HELIXYS
ENDOTRONICS, INC. RECEIVES $2 MILLION LINE OF CREDIT
ENDOTRONICS, INC. AND WHEATON SCIENCE PRODUCTS, INC. ANNOUNCE MARKETING AND DISTRIBUTION AGREEMENT
ENDOTRONICS REPORTS FOURTH-QUARTER AND FISCAL 1992 YEAR-END RESULTS
ENDOTRONICS, INC. UPGRADES PRODUCTION FACILITY AND SIGNS CYTOGEN CORPORATION CONTRACT
ENDOTRONICS REPORTS RESULTS FOR ITS FIRST QUARTER ENDED DEC. 31, 1992

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters